

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2004/025589

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/11 C12P19/34 C07H21/02 C07H21/04 A01N43/04
A61K31/713

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| Y | WO 00/05366 A (UNIVERSITY OF OTTAWA; KORNELUK, ROBERT, G; HOLCIK, MARTIN; LISTON, PET) 3 February 2000 (2000-02-03) page 9, line 23 - page 10, line 4 | 1-32, 34 |
| Y | WO 02/44321 A (MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V; TUSCHL,) 6 June 2002 (2002-06-06) claims 1-47 | 1-32, 34 |
| | ----- -/-- | |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

22 June 2005

Date of mailing of the international search report

23. 09. 2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Barnas, C

INTERNATIONAL SEARCH REPORT

 International Application No
 PCT/US2004/025589

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|------------------------------|
| P,X | CHAWLA-SARKAR M ET AL: "Trail-resistant cells sensitized to apoptosis by selective down regulation by siRNAs to inhibitors of apoptosis bcl-2, FLIP, survivin or XIAP." EUROPEAN CYTOKINE NETWORK, vol. 14, no. Supplement 3, September 2003 (2003-09), page 112, XP009042059 & ANNUAL MEETING OF THE INTERNATIONAL CYTOKINE SOCIETY; DUBLIN, IRELAND; SEPTEMBER 20-24, 2003 ISSN: 1148-5493 abstract | 1,3-9, 23,24, 27-32,34 |
| P,X | BURSTEIN EZRA ET AL: "A novel role for XIAP in copper homeostasis through regulation of MURR1." THE EMBO JOURNAL. 14 JAN 2004, vol. 23, no. 1, 14 January 2004 (2004-01-14), pages 244-254, XP002332238 ISSN: 0261-4189 page 252, right-hand column, paragraph 5 figure 5A published online 18. December 2003 | 1,3-9, 23,24, 27-32,34 |
| P,X | LIMA RAQUEL T ET AL: "Specific downregulation of bcl-2 and XIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells" CANCER GENE THERAPY, vol. 11, no. 5, May 2004 (2004-05), pages 309-316, XP002332239 ISSN: 0929-1903 page 310, left-hand column, paragraph 1 | 1,3-9, 23,24, 27-32,34 |

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-32, 34

A double stranded short interfering nucleic acid (siNA) molecule that directs cleavage of a XIAP RNA via RNA interference as described in claim 1.

2. claims: 33, 35 (part)

A double stranded short interfering nucleic acid (siNA) molecule that directs cleavage of a XIAP RNA via RNA interference wherein said siNA comprises any of SEQ ID NOs: 1-36, 468-503.

3. claims: 33, 35 (part)

A double stranded short interfering nucleic acid (siNA) molecule that directs cleavage of a XIAP RNA via RNA interference wherein said siNA comprises any of SEQ ID NOs: 37-72, 504-539.

4. claims: 33, 35 (part)

A double stranded short interfering nucleic acid (siNA) molecule that directs cleavage of a XIAP RNA via RNA interference wherein said siNA comprises any of SEQ ID NOs: 73-108, 540-575.

5. claims: 33, 35 (part)

A double stranded short interfering nucleic acid (siNA) molecule that directs cleavage of a XIAP RNA via RNA interference wherein said siNA comprises any of SEQ ID NOs: 109-144, 576-611.

6. claims: 33, 35 (part)

A double stranded short interfering nucleic acid (siNA) molecule that directs cleavage of a XIAP RNA via RNA interference wherein said siNA comprises any of SEQ ID NOs: 145-180, 612-647.

7. claims: 33, 35 (part)

A double stranded short interfering nucleic acid (siNA) molecule that directs cleavage of a XIAP RNA via RNA interference wherein said siNA comprises any of SEQ ID NOs:433-467, 900-934.

15. claims: 33, 35 (part)

A double stranded short interfering nucleic acid (siNA) molecule that directs cleavage of a XIAP RNA via RNA interference wherein said siNA comprises any of SEQ ID NOs:935-1056.
